Franceschi, S, Raza, SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Letters
2009; 286: 5–8.
World Health Organization. Hepatitis B vaccines. WHO Weekly Epidemiological Record
2009; 84: 405–419.
Romano, L, et al.
The worldwide impact of vaccination on the control and protection of viral hepatitis B. Digestive and Liver Disease
2011; 43 (Suppl. 1): S2–7.
Van Damme, P, Keunen, K, Beutels, P. Universal hepatitis B vaccination in Flanders: a martyrdom or an example of good policy? Anatomy of policy making. Tijdschrift voor Geneeskunde
2002; 58: 231–239.
Vellinga, A, Depoorter, AM, Van, Damme P. Vaccination coverage estimates by EPI cluster sampling survey of children (18–24 months) in Flanders, Belgium. Acta Paediatrica
2002; 91: 599–603.
Swennen, B, et al.
Analysis of factors influencing vaccine uptake: perspectives from Belgium. Vaccine
2001; 20: S5–S7.
Theeten, H, et al.
Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. Vaccine
2007; 25: 4940–4948.
Vandermeulen, C, et al.
Vaccination coverage in 14-year-old adolescents: Documentation, timeliness, and sociodemographic determinants. Pediatrics
2008; 121: E428–E434.
Swennen, B, et al. Vaccination coverage survey in infants at 18–24 months of age in Brussels-Capital Region. Report requested by the Common Community Commission of Brussels-Capital Region, 2000.
Hoppenbrouwers, K, et al.
Vaccination coverage survey in infants and adolescents in Flanders in 2008
. Brussels, Belgium, 2009.
Swennen, B, Robert, E. Vaccination coverage survey in infants at 18–24 months of age in the French community (except Brussels). Brussels, Belgium: PROVAC-Université Libre de Bruxelles, 2003.
Swennen, B, Robert, E. Vaccination coverage survey in infants at 18-24 months of age in the French community (except Brussels). Brussels, Belgium: PROVAC-Université Libre de Bruxelles, 2009.
Beutels, M, et al.
Prevalence of hepatitis A, B and C in the Flemish population. European Journal of Epidemiology
1997; 13: 275–280.
Van Loock, F, Rubbens, C. Survey of hepatitis B prevalence in the French Community, Belgium. Brussels, Belgium: Scientific Institute of Public Health, 1994.
Nardone, A, et al.
A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiology and Infection
2009; 137: 961–969.
Quoilin, S, et al.
A population-based prevalence study of hepatitis A, B and C virus using oral fluid in Flanders, Belgium. European Journal of Epidemiology
2007; 22: 195–202.
Theeten, H, et al.
Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium. Epidemiology and Infection
2011; 139: 494–504.
Kafatos, G, Andrews, N, Nardone, A. Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine
2005; 23: 5022–5027.
Kafatos, G, et al.
The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virus. Journal of Viral Hepatitis
2007; 14: 260–268.
Van Damme, P, et al.
Hepatitis B vaccines. In: Plotkin, S, Orenstein, WA, Offit, P, eds. Vaccines, 6th edn. Philadelphia: Saunders, Elsevier, 2013, pp 205–234.
Zanetti, AR, et al.
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet
2005; 366: 1379–1384.
Gilca, V, et al.
Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine
2013; 31: 448–451.
Bauer, T, Jilg, W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine
2006; 24: 572–577.
Anon. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet
2000; 355: 561–565.
Leuridan, E, Van, Damme P. Hepatitis B and the need for a booster dose. Clinical Infectious Diseases
2011; 53: 68–75.
Mereckiene, J, et al.
Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009?
2010; 28: 4470–4477.
Mackroth, MS, et al.
Immunizing school-age children and adolescents: experience from low- and middle-income countries. Vaccine
2010; 28: 1138–1147.
Cawley, J, Hull, HF, Rousculp, MD. Strategies for implementing school-located influenza vaccination of children: a systematic literature review. Journal of School Health
2010; 80: 167–175.
Gidding, HF, et al.
The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine
2007; 25: 8637–8641.
Mele, A, et al.
Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clinical Infectious Diseases
2008; 46: 868–875.
Bonanni, P, et al.
Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine
2003; 21: 685–691.
Anon. Surveillance and prevention of vaccine preventable hepatitis. Data on surveillance and prevention of hepatitis A and B in 22 countries 1990s-2001 (www.eurohep.net). Accessed 30 August 2010. Antwerp, Belgium: Centre for the Evaluation of Vaccination, University of Antwerp.
Cai, W, et al.
Hepatitis B virus infections among children and adolescents in Germany: migration background as a risk factor in a low seroprevalence population. Pediatric Infectious Disease Journal
2010; 30: 19–24.
Hahne, SJ, et al.
Prevalence of hepatitis B virus infection in The Netherlands in 1996 and 2007. Epidemiology and Infection
2012; 140: 1469–1480.
Merrill, RM, Hunter, BD. Seroprevalence of markers for hepatitis B viral infection. International Journal of Infectious Diseases
2011; 15: e78–121.